Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US11773150B2 · kind B2 · utility
0Cited by
11References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 27, 2020 |
| Grant date | Oct 3, 2023 |
| Priority date | — |
| Expiry date | Aug 27, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.